● Enters a Fast-Growing Business Sector with a Primary $15 Billion TAM and 19% CAGRs
● Expects its Disruptive Digital Telecom Software and Services Business Revenue to Accelerate in 2025 and Beyond
● Company Initially Targets $5 Million Monthly Revenue Run Rate for Q2 and $10 Million Monthly Revenue Run Rate in Q3
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025
PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024
Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025
Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025
Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028
Read More
Date: March 31, 2025, 10:36 A.M.
Location: Moderated Poster Theater 7
PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION
Read More
With the addition of SBG injections, the West Palm Beach integrative health clinic offers a new option to individuals looking for relief from chronic pain, trauma disorder, and other ailments
Read More
Education event for occupational and environmental medicine physicians will cover biomechanics, research and clinical indications for use of long-duration ultrasound treatment for soft-tissue injury healing.
Read More
